Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

This study has suspended participant recruitment.
(Study cancelled.)
Sponsor:
Information provided by (Responsible Party):
Prolong Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01374165
First received: May 26, 2011
Last updated: January 5, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given